[Why do we need registries of patients on biologics drugs?].
نویسندگان
چکیده
Significant data on applied biologic drugs can be found in national registries of treated patients. The main reason of establishing registries is monitoring the efficacy and safety of biologic drugs in long-term treatment. Registries provide information on outcome of the disease, life quality, and risk-benefit ratio including society costs.
منابع مشابه
Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
Over the past decade, the use of biologics has significantly changed the management of rheumatoid arthritis (RA). Biologics selectively target components of the immune system, resulting in better disease control. However, the growing use of biologics in RA has increased safety concerns among rheumatologists. Randomized controlled trials (RCTs) and registries are the most reliable sources of cli...
متن کاملDo biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.
OBJECTIVES The aim was to study the incidence of joint replacements among biologic drug and disease-modifying anti-rheumatic drug (DMARD) users as well as to investigate the plausible effect of biologic treatment on survival of prostheses in patients with Rheumatoid arthritis (RA). METHODS The study population comprised 2 cohorts of patients [Register of biologic treatment in Finland (ROB-FIN...
متن کاملAll It Takes for Corruption in Health Systems to Triumph, Is Good People Who Do Nothing; Comment on “We Need to Talk About Corruption in Health Systems”
Numerous investigations demonstrate that the problem of corruption in the health sector is enormous and has grave negative consequences for patients. Nevertheless, the problem of corruption in health systems is far from eminent in the international health policy debate. Hutchinson, Balabanova, and McKee have identifed in their Editorial five reasons why the health policy community has been relu...
متن کاملThe role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The US Food and Drug Administration has approved ADA as a medication for use in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and juvenile idiopathic arthritis. This year marks 10 years of clinical experience with A...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Reumatizam
دوره 57 2 شماره
صفحات -
تاریخ انتشار 2010